Genedrive (LON: GDR) said it has been successful with its tender into Public Health England (PHE) under Lot 1 of the National Microbiology Framework.
The PHE tender sought to appoint suppliers to a multi-lot national microbiology framework agreement relating to the supply of Diagnostics Goods and Services and covering Clinical Laboratory Diagnostic Testing Services.
The AIM-listed company said the framework contract is not exclusive to them or a guarantee of orders, but it allows participating authorities to issue call-off orders for products in the future.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
Genedrive said all of its CE marked products fall within the framework agreement.
David Budd, CEO of genedrive, said: “We are very pleased to have received notice of this contract award decision and look forward to the opportunity to engage with PHE and relevant authorities on future potential contracts. This is an early notification of the decision and we will update shareholders when we have more information on what this contract may mean for orders and revenues”.
Genedrive’s share price is trading over 8.7% higher following the news, at 72.9p.
Should you invest in Genedrive shares?
Genedrive shares are traded on the London stock exchange’s AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Genedrive shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies